A Universal Protocol for Large-scale gRNA Library Production from any DNA Source

Executive Industry Relevance

Generating comprehensive guide RNA libraries from any DNA source enables scalable CRISPR-based screening for target validation and functional genomics. The CORALINA method reduces cost and complexity compared to oligonucleotide synthesis, supporting early discovery workflows. This approach enhances predictive confidence in therapeutic hypothesis testing by providing unbiased, genome-scale gRNA libraries.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of all possible genomic sites from input DNA for unbiased target hypothesis testing.
• Operational Value: Eliminates sequence design constraints and synthesis costs associated with traditional gRNA library generation.
• Predictive Value: Supports functional target validation by enabling phenotypic screening across entire genomes or custom DNA sources.

Screening & Assay Development

• Scientific Value: Produces standardized gRNA fragments in the 18–30 bp range for consistent cloning into expression vectors.
• Operational Value: Uses gel-based size selection and phenol-chloroform extraction to ensure fragment purity for downstream ligation.
• Assay Readiness: Generates linker-amplified fragments validated by restriction digestion and PCR for directional cloning into gRNA backbones.

Translational & Preclinical Research

• Translational Continuity: Enables generation of gRNA libraries from disease-relevant DNA sources such as patient-derived samples or model organism genomes.
• Preclinical Application: Supports target de-risking in validation studies by providing comprehensive gRNA coverage for CRISPR-based functional assays.
• Mechanistic De-risking: Facilitates pathway and target clarification through unbiased screening, reducing false negatives in target identification.

Pipeline & Workflow Integration

The CORALINA method fits within the early discovery phase, enabling library preparation for CRISPR screening workflows that inform lead identification and preclinical target prioritization.

• Discovery Biology: Supports hypothesis-free target identification by generating gRNAs from any genomic or epigenomic DNA source.
• Screening: Produces purified DNA fragments ready for ligation into gRNA expression vectors, enabling scalable library construction.
• Analytics: Relies on gel electrophoresis, spectrophotometry, and colony counting to quantify library complexity and cloning efficiency.
• Translational Research: Allows use of clinically relevant DNA inputs to bridge discovery with preclinical models.
• Enterprise Reuse: Protocol can be standardized across teams for repeated gRNA library generation from diverse DNA sources.

Operational & Enterprise Impact

• Scientific Value: Enables comprehensive, unbiased gRNA library generation for high-confidence target validation.
• Operational Value: Reduces reagent costs and simplifies workflow compared to array-based oligonucleotide synthesis.
• Strategic Value: Improves go/no-go decision quality by increasing target coverage and reducing biological false negatives.
• Portfolio Impact: Supports risk-adjusted target prioritization through genome-scale screening data from flexible DNA inputs.

Implementation Considerations

• Requires expertise in molecular cloning, gel electrophoresis, and nucleic acid purification.
• Dependent on micrococcal nuclease optimization, PAGE equipment, and restriction enzyme workflows.
• Needs standardization of gel excision, DNA extraction, and ligation steps across users and batches.
• Must adapt input DNA quality and quantity for different sources (e.g., genomic, BAC, plasmid).
• Practical limitation: Library complexity depends on input DNA diversity and effective size selection of 18–30 bp fragments.

Biopharma FAQs